Form 8-K - Current report:
SEC Accession No. 0001193125-24-287172
Filing Date
2024-12-31
Accepted
2024-12-31 16:05:31
Documents
16
Period of Report
2024-12-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d900232d8k.htm   iXBRL 8-K 27036
2 EX-3.1 d900232dex31.htm EX-3.1 473345
3 EX-10.1 d900232dex101.htm EX-10.1 274305
7 GRAPHIC g900232g1228091241288.jpg GRAPHIC 4588
  Complete submission text file 0001193125-24-287172.txt   1013090

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA rprx-20241231.xsd EX-101.SCH 2855
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE rprx-20241231_lab.xml EX-101.LAB 17979
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rprx-20241231_pre.xml EX-101.PRE 11261
19 EXTRACTED XBRL INSTANCE DOCUMENT d900232d8k_htm.xml XML 3764
Mailing Address 110 EAST 59TH STREET NEW YORK NY 10022
Business Address 110 EAST 59TH STREET NEW YORK NY 10022 (212) 883-0200
Royalty Pharma plc (Filer) CIK: 0001802768 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39329 | Film No.: 241593035
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)